Targeting the lactate transporter protein MCT-1/miR-34a/IL-6/IL-6R signaling axis has also been reported to inhibit epithelial mesenchymal transition, tumor stemness and M2 macrophage polarization in triple-negative breast cancer (109), in addition, MCT1-targeted drug AZD3956 is currently in clinical trials (NCT01791595). Here, SLC16A1 is linked to neoplasm.